About Dr. Alexander Valvezan
Alexander Valvezan is an Assistant Professor of Pharmacology at the Rutgers Robert Wood Johnson Medical School, Full Member of the Rutgers Cancer Institute of New Jersey, and Resident Faculty Member in the Center for Advanced Biotechnology and Medicine. Dr. Valvezan completed his PhD at the University of Pennsylvania in the laboratory of Dr. Peter Klein, studying the Wnt signaling pathway in embryonic development and cancer. He then joined the laboratory of Dr. Brendan Manning at Harvard University as a postdoctoral fellow, studying tumor metabolism and the mTOR signaling and metabolic network. Dr. Valvezan’s current research interests focus on understanding how signaling pathways coordinate metabolic networks to promote cell growth, with emphasis on the impact of common oncogenic mutations, and the goal of exploiting unique tumor dependencies for therapeutic benefit.
Education
- Postdoctoral Fellow, Harvard University
- Ph.D. Cell and Molecular Biology, University of Pennsylvania, 2013
- B.A. Biological Sciences, University of Delaware, 2006
Academic Appointments
- Department of Pharmacology (primary), Rutgers Robert Wood Johnson Medical School
- Department of Medicine (secondary), Rutgers Robert Wood Johnson Medical School
- Full Member, Rutgers Cancer Institute of New Jersey (CINJ), Cell Metabolism and Growth Program
- Resident Faculty Member, Center for Advanced Biotechnology and Medicine (CABM)
Honors and Awards
- 2023 DoD Tuberous Sclerosis Complex Research Program Award
- 2022 Ludwig Princeton Branch Cancer Metabolism Research Award
- 2022 Breast Cancer Alliance Young Investigator Award
- 2022 New Jersey Commission on Cancer Research Pediatric Cancer Award
- 2021 Leukemia Research Foundation Research Grant
- 2020 Rutgers Cancer Institute of New Jersey New Investigator Award
- 2019 Department of Defense Tuberous Sclerosis Complex Research Program Award